Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Ratios

C4 Therapeutics (CCCC) Shares Issued (2019 - 2026)

C4 Therapeutics has reported Shares Issued over the past 8 years, most recently at $605000.0 for Q1 2026.

For Q1 2026, Shares Issued changed N/A year-over-year to $605000.0; the TTM value through Mar 2026 reached $712000.0, down 99.14%, while the annual FY2025 figure was $107000.0, 86.25% down from the prior year.
Shares Issued for Q1 2026 was $605000.0 at C4 Therapeutics, up from $107000.0 in the prior quarter.
Over five years, Shares Issued peaked at $82.3 million in Q4 2024 and troughed at $2000.0 in Q2 2023.
A 5-year average of $7.0 million and a median of $173000.0 in 2022 define the central range for Shares Issued.
Biggest five-year swings in Shares Issued: crashed 99.23% in 2023 and later skyrocketed 6650.0% in 2024.
Year by year, Shares Issued stood at $47000.0 in 2022, then plummeted by 95.74% to $2000.0 in 2023, then soared by 4114900.0% to $82.3 million in 2024, then crashed by 99.87% to $107000.0 in 2025, then skyrocketed by 465.42% to $605000.0 in 2026.
Business Quant data shows Shares Issued for CCCC at $605000.0 in Q1 2026, $107000.0 in Q3 2025, and $82.3 million in Q4 2024.